Hepatitis Monthly

Published by: Kowsar

Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience

Ibrahim Halil Bahcecioglu 1 , * , Murat Ispiroglu 1 , Ulvi Demirel 1 and Mehmet Yalniz 1
Authors Information
1 Department of Gastroenterology, Faculty of Medicine, Firat University, Elazig, Turkey
Article information
  • Hepatitis Monthly: March 2015, 15 (3); e24366
  • Published Online: March 31, 2015
  • Article Type: Research Article
  • Received: October 6, 2014
  • Revised: February 6, 2015
  • Accepted: February 21, 2015
  • DOI: 10.5812/hepatmon.24366

To Cite: Bahcecioglu I H, Ispiroglu M, Demirel U, Yalniz M. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience, Hepat Mon. 2015 ;15(3):e24366. doi: 10.5812/hepatmon.24366.

Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther. 2007; 12(3): 381-8[PubMed]
  • 2. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977; 18(12): 997-1003[PubMed]
  • 3. Lau JY, Smith HM, Chaggar K, Hansen LJ, Portmann BC, Alexander GJ, et al. Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection. J Med Virol. 1991; 33(4): 273-6[PubMed]
  • 4. Koytak ES, Yurdaydin C, Glenn JS. Hepatitis d. Curr Treat Options Gastroenterol. 2007; 10(6): 456-63[PubMed]
  • 5. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol. 2006; 17(1): 25-34[PubMed]
  • 6. Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013; 18(3 Pt B): 541-8[DOI][PubMed]
  • 7. Rizzetto M. Hepatitis D: the comeback? Liver Int. 2009; 29 Suppl 1: 140-2[DOI][PubMed]
  • 8. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008; 28(4): 494-8[DOI][PubMed]
  • 9. Gunsar F. Treatment of delta hepatitis. Expert Rev Anti Infect Ther. 2013; 11(5): 489-98[DOI][PubMed]
  • 10. Berk L, de Man RA, Housset C, Berthelot P, Schalm SW. Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Prog Clin Biol Res. 1991; 364: 411-20[PubMed]
  • 11. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994; 14(3): 154-7[PubMed]
  • 12. Rosina F, Conoscitore P, Smedile A, Mangia A, Borghesio E, Martinotti R, et al. Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. Dig Liver Dis. 2002; 34(4): 285-9[PubMed]
  • 13. Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, Okcu-Heper A, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002; 37(2): 266-71[PubMed]
  • 14. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005; 22(3): 227-32[DOI][PubMed]
  • 15. Rizzetto M. Hepatitis D: clinical features and therapy. Dig Dis. 2010; 28(1): 139-43[DOI][PubMed]
  • 16. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014; 16(1): 365[DOI][PubMed]
  • 17. Rosina F, Saracco G, Lattore V, Quartarone V, Rizzetto M, Verme G, et al. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Prog Clin Biol Res. 1987; 234: 299-303[PubMed]
  • 18. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006; 44(3): 713-20[DOI][PubMed]
  • 19. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006; 26(7): 805-10[DOI][PubMed]
  • 20. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364(4): 322-31[DOI][PubMed]
  • 21. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013; 18(4): 561-6[DOI][PubMed]
  • 22. Samiullah S, Bikharam D. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012; 18(40): 5793-8[DOI][PubMed]
  • 23. Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon. 2011; 11(9): 731-5[DOI][PubMed]
  • 24. Ormeci N, Bolukbas F, Erden E, Coban S, Ekiz F, Erdem H, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011; 58(110-111): 1648-53[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader